Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Apr 26;8:6563. doi: 10.1038/s41598-018-24968-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Antitumor activity in HER2+ cells. (A) Viability of SKBR3 treated for 3, 5 or 7 days with 1 (left panel) or 10 (right panel) μg mL^–1 of free or nanoformulated TZ, or with equal concentrations of MNP (n = 6). Asterisks indicate significance vs. untreated cultures; § MNP-HC vs. TZ. (B) Western blot analysis of p27Kip1 expression in cells treated with 1 or 10 μg mL^–1 of free or nanoformulated TZ, or with equal concentrations of MNP. Densitometric quantification of p27Kip1 was relative to α-tubulin (n = 4). Asterisks indicate significance vs. untreated cells (Ctrl); § MNP-HC vs. TZ. (C) Cell cycle analysis of SKBR3 treated with MNP-HC, MNP or TZ for 72 h. Results are mean percentage of cells in G1, S or G2/M phase (n = 7). Asterisks indicate significance vs. untreated cells (Ctrl). (D) The percentage of apoptotic cells was determined upon 24 or 72 h of treatment with MNP-HC, MNP or TZ (15 μg mL⁻¹), and compared to untreated cells (Ctrl, n = 6).